SELLAS Life Sciences Group, Inc (SLS) Financials

SLS Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 8.1 million 11.9 million
2023-06-30 18.6 million 13.7 million
2023-03-31 29.1 million 15.9 million
2022-12-31 20.9 million 16.1 million

SLS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -9.9 million 543000
2023-06-30 -7.6 million 514000
2023-03-31 -12.1 million 540000
2022-12-31 -9.7 million 446000

SLS Net Income

No data available :(

SLS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 4.0 million - 644000
2023-06-30 13.8 million - 749000
2023-03-31 23.9 million - 849000
2022-12-31 17.1 million - 945000

SLS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 28.4 million
2023-06-30 28.3 million
2023-03-31 23.5 million
2022-12-31 19.4 million

SLS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 3.0 million 5.8 million 3.5 million -
2023-06-30 - 5.9 million 3.1 million -
2023-03-31 - 7.2 million 4.1 million -
2022-12-31 4.5 million 5.8 million 3.6 million -

SLS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - -
2023-06-30 - 158000
2023-03-31 - 87000
2022-12-31 -1.0 million 100000

SLS

Price: $1.35

52 week price:
0.50
1.91

Earnings Per Share: -1.34 USD

P/E Ratio: -0.50

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 183300

Ebitda: -4.4 million

Market Capitalization: 76.5 million

Links: